Erschienen in:
01.09.2008 | Retinal Disorders
A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports)
verfasst von:
Mitzy E. Torres-Soriano, Gerardo García-Aguirre, Verónica Kon-Jara, Orlando Ustariz-Gonzáles, Maura Abraham-Marín, Michael D. Ober, Hugo Quiroz-Mercado
Erschienen in:
Graefe's Archive for Clinical and Experimental Ophthalmology
|
Ausgabe 9/2008
Einloggen, um Zugang zu erhalten
Abstract
Background
We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC).
Methods
Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment.
Results
All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment.
Conclusions
Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.